Exscientia announces sixth molecule created through generative ai platform to enter clinical stage

Oxford, england--(business wire)--exscientia plc (nasdaq: exai) today announced that sumitomo pharma co., ltd. (‘sumitomo pharma') plans to initiate a phase 1 clinical study of dsp-2342 in the united states. dsp-2342 is a highly-selective bispecific small molecule with potent dual 5-ht2a and 5-ht7 antagonist activity with broad potential in psychiatric disease. it is the third molecule created utilising exscientia's ai-driven drug discovery platform under a collaboration with sumitomo pharma, r.
EXAI Ratings Summary
EXAI Quant Ranking